---
document_datetime: 2026-01-30 10:38:43
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vizamyl-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vizamyl-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.5846946
conversion_datetime: 2026-02-01 20:38:40.823326
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## VIZAMYL

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 30/01/2026                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323949   | variations.   | II, Labelling and PL   |
|---------------------|---------------|------------------------|

<div style=\"page-break-after: always\"></div>

| manufacturing process of the active - B.I.b.2.a Minor changes to an test procedure - Accepted   |
|-------------------------------------------------------------------------------------------------|
| substance                                                                                       |
| approved                                                                                        |
| A. ADMINISTRATIVE CHANGES - A.7                                                                 |
| Deletion of manufacturing sites for an active                                                   |
| substance, intermediate or finished product,                                                    |
| packaging site, manufacturer responsible for                                                    |
| batch release, site where batch control takes                                                   |
| place, or supplier of a starting material,                                                      |
| reagent or excipient (when mentioned in the                                                     |
| dossier)* - Accepted                                                                            |
| A. ADMINISTRATIVE CHANGES - A.7                                                                 |
| Deletion of manufacturing sites for an active                                                   |
| substance, intermediate or finished product,                                                    |
| packaging site, manufacturer responsible for                                                    |
| batch release, site where batch control takes                                                   |
| place, or supplier of a starting material,                                                      |
| reagent or excipient (when mentioned in the                                                     |
| dossier)* - Accepted                                                                            |
| A. ADMINISTRATIVE CHANGES - A.7                                                                 |
| Deletion of manufacturing sites for an active                                                   |
| substance, intermediate or finished product,                                                    |
| packaging site, manufacturer responsible for                                                    |
| batch release, site where batch control takes                                                   |
| place, or supplier of a starting material,                                                      |
| reagent or excipient (when mentioned in the                                                     |
| dossier)* - Accepted                                                                            |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000318931   | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted   | 28/01/2026   | Annex II and PL   |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------|
| Variation type IA / EMA/VR/0000312794   | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/11/2025   | Annex II and PL   |

<div style=\"page-break-after: always\"></div>

| place, or supplier of a starting material,    |
|-----------------------------------------------|
| reagent or excipient (when mentioned in the   |
| dossier)* - Accepted                          |
| A. ADMINISTRATIVE CHANGES - A.7               |
| Deletion of manufacturing sites for an active |
| substance, intermediate or finished product,  |
| packaging site, manufacturer responsible for  |
| batch release, site where batch control takes |
| place, or supplier of a starting material,    |
| reagent or excipient (when mentioned in the   |
| dossier)* - Accepted                          |
| A. ADMINISTRATIVE CHANGES - A.7               |
| Deletion of manufacturing sites for an active |
| substance, intermediate or finished product,  |
| packaging site, manufacturer responsible for  |
| batch release, site where batch control takes |
| place, or supplier of a starting material,    |
| reagent or excipient (when mentioned in the   |
| dossier)* - Accepted                          |
| A. ADMINISTRATIVE CHANGES - A.7               |
| Deletion of manufacturing sites for an active |
| substance, intermediate or finished product,  |
| packaging site, manufacturer responsible for  |
| batch release, site where batch control takes |
| place, or supplier of a starting material,    |
| reagent or excipient (when mentioned in the   |
| dossier)* - Accepted                          |
| A.5 Change in the name and/or address of a    |

<div style=\"page-break-after: always\"></div>

|                                          | manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.a Tightening of specification limits - Accepted                                                                                                                                                                                                                                                                                            |            |                            |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------|
| Variation type IA_IN / EMA/VR/0000296322 | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of | 22/09/2025 | Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                            | a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |                                                                                                                                                                                                                                                             |
|----------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248481 | - -                                                                                         | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing flutemetamol (18f) remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |